US Pricing Reform Puts Cancer Drug Innovation At Risk, Drug Leaders Warn

 
• By Jessica Merrill

Merck & Co. CEO Rob Davis, Regeneron president George Yancopoulos, Pfizer R&D president Mikael Dolsten and others weighed in at the Galien Forum on the potential impact of the US Inflation Reduction Act on innovation.

Galien CEO Panel
Industry leaders discussed impacts of the IRA at the Galien Forum • Source: Galien

More from R&D

More from Scrip